Evidence map›Paper›PMID 40487407›Full record

SynthesisFrontiers in pharmacology2025

Therapeutic efficacy and mechanisms of Xuebijing in

Jiaqi Li, Yihan Sun, Hao Wen, Boying Xiao, Jianming Wang, Ziqi Li, Lei Wang, Meiyu Yu

Abstract readSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jiaqi Li *Department of Trauma Center, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Yihan Sun *Department of Trauma Center, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Hao WenDepartment of Trauma Center, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Boying XiaoDepartment of Trauma Center, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Jianming WangDepartment of General Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Ziqi LiDepartment of Trauma Center, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Lei WangDepartment of General Surgery, The First Hospital of China Medical University, Shenyang, Liaoning, China.
Meiyu YuDepartment of Trauma Center, The First Hospital of China Medical University, Shenyang, Liaoning, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Xuebijing (XBJ) is a traditional Chinese medicine widely used in China for managing sepsis, systemic inflammatory response syndrome, and multiple organ dysfunction secondary to severe infections. This study aimed to assess the therapeutic efficacy and safety of XBJ as an adjuvant treatment for Materials and methods: A systematic search was conducted across multiple databases for randomized controlled trials (RCTs) evaluating XBJ in Results: A total of 11 RCTs involving 1,035 patients met the inclusion criteria. Meta-analysis demonstrated that XBJ significantly improved clinical outcomes, with a higher overall effective rate (RR = 1.20, 95% CI: 1.13-1.27, Conclusion: XBJ appears effective and safe as an adjuvant therapy for Systematic Review Registration: https://www.crd.york.ac.uk/prospero/, identifier CRD42023486389.

Indexed as

Acinetobacter baumanniimeta-analysismolecular dockingmolecular dynamics simulationsnetwork pharmacologyXuebijing

Identifiers

PMID40487407
PMCPMC12141340

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.